The specifics of pathogenetic prevention of thrombotic and hemorrhagic complications in patients with gynecological cancers

Abstract

The article tells about major anticoagulant medications used in cancer patients taking into account the pathogenesis of hypercoagulation status in these patients: oral anticoagulants, heparin medications, selective factor Xa-inhibitors. The main advantages of low molecular weight heparins versus unfractionated heparin are described. Recommendations for the prevention of thrombotic complications in cancer patients are provided. Possible complications of heparin therapy are reviewed, and the prevention methods are suggested.